Lung Cancer | Specialty

Dr. Gitlitz Discusses the Genomics of Young Lung Cancer Study

September 9th 2015

Barbara J. Gitlitz, MD, from the University of Southern California, discusses results and key takeaways from The Genomics of Young Lung Cancer Study.

Nivolumab/Ipilimumab Combination Active in Advanced NSCLC

September 8th 2015

A chemotherapy-free regimen of nivolumab and ipilimumab demonstrated activity as a first-line therapy for patients with advanced non–small cell lung cancer.

Nivolumab Survival Benefit Sustained in Squamous NSCLC

September 8th 2015

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Actionable Mutations Common in Young Lung Cancer Patients

September 8th 2015

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

Bevacizumab Triplet Improves Survival in Mesothelioma

September 8th 2015

Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.

Dr. Govindan on the Genomic Characterization of Large-Cell Neuroendocrine Lung Tumors

September 7th 2015

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

Atezolizumab Plus Chemo Leads to High Response Rate in NSCLC

September 7th 2015

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

Dr. Vokes on Screening, Epidemiology, and Smoking in Lung Cancer

September 7th 2015

Everett E. Vokes, MD, chair, Department of Medicine, investigator of head and neck and lung cancer, University of Chicago, discusses a plenary session that covered prevention and screening at the 16th World Conference on Lung Cancer.

MCNA Priority Review, Afatinib Application Accepted, ASCO NSCLC Guidelines, and More

September 4th 2015

Dr. James Stevenson on Standardized Care Pathways for NSCLC Treatment

September 4th 2015

James Stevenson, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute (TCI), discusses the impact of a stage IV non-small-cell lung cancer (NSCLC) care pathway on front-line and maintenance chemotherapy.

FDA Grants Nivolumab Priority Review in Nonsquamous NSCLC

September 2nd 2015

Nivolumab (Opdivo) has received an FDA priority review designation for patients with previously treated nonsquamous non–small cell lung cancer.

ASCO Updates Stage IV NSCLC Treatment Guideline

August 31st 2015

ASCO has updated their clinical practice guideline for the treatment of patients with stage IV non-small cell lung cancer, placing greater emphasis on the selection of targeted therapies.

Necitumumab Assigned "Low Value" in Lung Cancer by Emory and Georgia Tech

August 28th 2015

New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.

Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

August 28th 2015

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

Rapidly Evolving Lung Cancer Treatment Landscape

August 27th 2015

Checkpoint Inhibitors for Malignant Pleural Mesothelioma

August 27th 2015

Immunotherapy AEs and Treatment Duration in NSCLC

August 27th 2015

Checkpoint Inhibitors in Small-Cell Lung Cancer

August 27th 2015

Frontline Immunotherapy Combinations for NSCLC

August 27th 2015

Checkpoint Inhibitor Biomarkers for Lung Cancer

August 27th 2015